Ionis, AstraZeneca To Use Real-World Data To Accelerate RNA-Targeting Cholesterol Drug
Phase I Shows Promise, But ION449 Must Catch Up With Inclisiran
Early data presented at the American Heart Association showed strong PCSK9 and LDL cholesterol lowering for ION449; AstraZeneca plans rapid development under an RWE-based FDA pilot program.
You may also be interested in...
AstraZeneca has bulked up its late-stage pipeline with an agreement for Ionis’s eplontersen which is in trials for two rare diseases, quelling some analysts’ fears about the scarcity of catalysts for next year.
Join us for a brief audio tour around the past week's key developments in the global biopharma industry, in this podcast version of Scrip's Five Must-Know Things.
Timing means full EU approval could coincide with US FDA authorization later this year.